Company news

Ocular Therapeutix, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ocular Therapeutix™ to Present at Two Investor Conferences in March

February 24, 2025

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

February 23, 2025

Ocular Therapeutix™ Announces Upcoming Presentations at the Angiogenesis, Exudation, and Degeneration 2025 Virtual Meeting

February 2, 2025

Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR

January 13, 2025

Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

January 7, 2025

Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 9, 2024

Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1

December 1, 2024

Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences

November 25, 2024

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights

November 13, 2024

Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV

November 12, 2024

Ocular Therapeutix™ Appoints Namrata Saroj, OD, as Chief Business Officer

November 11, 2024

Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024

November 5, 2024

Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD

October 14, 2024

Ocular Therapeutix™ to Present at October Ophthalmology Meetings

October 8, 2024

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

September 24, 2024

Ocular Therapeutix™ to Present at September Retina Meetings

September 4, 2024

Ocular Therapeutix™ to Present at Two Investor Conferences in September

September 3, 2024

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8, 2024

Ocular Therapeutix™ Reports Second Quarter 2024 Results

August 6, 2024

Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

August 6, 2024

Ocular Therapeutix™ to Report Second Quarter 2024 Financial Results on August 7, 2024

July 30, 2024

Ocular Therapeutix™ Announces First Patients Enrolled in Phase 3 SOL-R Wet AMD Study

July 29, 2024

Ocular Therapeutix™ Announces Late-Breaking Abstract of HELIOS Study to be Presented at 42nd ASRS Annual Scientific Meeting

July 9, 2024

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

June 12, 2024

Ocular Therapeutix® to Host Investor Day on June 13, 2024

June 4, 2024

Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 3, 2024

Ocular Therapeutix™ Reports First Quarter 2024 Results

May 6, 2024

Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences

May 5, 2024

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 5, 2024

Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024

May 2, 2024

Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024

April 30, 2024

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

April 17, 2024

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

April 15, 2024

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

April 14, 2024

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

April 8, 2024

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

April 5, 2024

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

March 25, 2024

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

March 10, 2024

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

March 4, 2024

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

February 21, 2024

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

February 21, 2024

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

February 21, 2024

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

February 14, 2024

Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

February 12, 2024

Ocular Therapeutix™ Announces FDA Agreement to Amend Special Protocol Assessment (SPA) for Pivotal Clinical Trial of AXPAXLI™ in Wet AMD

January 24, 2024

Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

December 17, 2023

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

December 12, 2023

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock

December 12, 2023

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

November 7, 2023

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

November 6, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.